Income Statement Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 01:30:00 2026-02-13 EST			5-day change	1st Jan Change
5,614.00 ^JPY	+0.09%		+1.76%	+16.11%

02-10	Takeda Pharmaceutical Says NDA for Oveporexton Gets FDA Acceptance	MT
02-10	U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda Pharmaceutical Company Limited's Oveporexton (TAK-861) as A Potential First-In-Class Therapy for Narcolepsy Type 1	CI

fe2e8e4.xizNZeRLB_O9dVzA2PMA7XVl37i53AZmf7S_PMlepBA.r3a0UbsgY8PeOjSJ7JhGiiQQ6M7Ns0VUDsaIf_8c80PyfJwz0ihsqcskPw

Published financial data: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2021	2022	2023	2024	2025
Revenues	3,198B	3,569B	4,027B	4,264B	4,582B
Total Revenues	3,198B	3,569B	4,027B	4,264B	4,582B
Cost of Goods Sold, Total	994B	1,127B	1,253B	1,432B	1,571B
Gross Profit	2,204B	2,442B	2,774B	2,832B	3,010B
Selling General & Admin Expenses, Total	876B	886B	997B	1,054B	1,105B
R&D Expenses	456B	526B	633B	729B	730B
Amortization of Goodwill and Intangible Assets - (IS)	405B	419B	485B	522B	548B
Other Operating Expenses	43.49B	10.99B	38.99B	35.06B	64.05B
Other Operating Expenses, Total	1,780B	1,842B	2,155B	2,339B	2,447B
Operating Income	424B	600B	620B	493B	563B
Interest Expense, Total	-131B	-122B	-117B	-115B	-130B
Interest And Investment Income	2.15B	4.76B	5.78B	11.63B	19.98B
Net Interest Expenses	-129B	-118B	-111B	-104B	-111B
Income (Loss) On Equity Invest.	76M	-15.37B	-8.63B	6.47B	-3.99B
Currency Exchange Gains (Loss)	-97.32B	-1.79B	-9.73B	-13.61B	786M
Other Non Operating Income (Expenses)	83.17B	-30.4B	3.98B	-31.52B	-24.86B
EBT, Excl. Unusual Items	281B	434B	494B	351B	424B
Restructuring Charges	-116B	-83.84B	-59.23B	-81.36B	-128B
Merger & Related Restructuring Charges	-	-	-	-	-
Impairment of Goodwill	-	-	-	-	-
Gain (Loss) On Sale Of Investments	-	8.48B	22.42B	-	-18.88B
Gain (Loss) On Sale Of Assets	235B	8.16B	8.9B	7.98B	10.56B
Asset Writedown	-17.6B	-54.42B	-62.48B	-140B	-103B
Insurance Settlements	479M	556M	-	-	-
Legal Settlements	-17.4B	-20.32B	-16.46B	-45.21B	-
Other Unusual Items	595M	9.66B	-12.14B	-39.62B	-9.45B
EBT, Incl. Unusual Items	366B	303B	375B	52.79B	175B
Income Tax Expense	-9.94B	72.4B	58.05B	-91.41B	66.94B
Earnings From Continuing Operations	376B	230B	317B	144B	108B
Net Income to Company	376B	230B	317B	144B	108B
Minority Interest	-166M	-107M	-21M	-130M	-215M
Net Income - (IS)	376B	230B	317B	144B	108B
Net Income to Common Incl Extra Items	376B	230B	317B	144B	108B
Net Income to Common Excl. Extra Items	376B	230B	317B	144B	108B
Per Share Items
Net EPS - Basic	240.72	147.14	204.29	92.09	68.36
Basic EPS - Continuing Operations	240.72	147.14	204.29	92.09	68.36
Basic Weighted Average Shares Outstanding	1.56B	1.56B	1.55B	1.56B	1.58B
Net EPS - Diluted	238.96	145.87	201.94	91.16	67.23
Diluted EPS - Continuing Operations	238.96	145.87	201.94	91.16	67.23
Diluted Weighted Average Shares Outstanding	1.57B	1.58B	1.57B	1.58B	1.61B
Normalized Basic EPS	112.3	173.53	198.98	140.07	167.85
Normalized Diluted EPS	111.47	172.03	196.69	138.66	165.08
Dividend Per Share	180	180	180	188	196
Payout Ratio	75.36	123.3	88.14	199.34	280.28
American Depositary Receipts Ratio (ADR)	0.5	0.5	0.5	0.5	0.5
Supplemental Items
EBITDA	917B	1,112B	1,211B	1,138B	1,233B
EBITA	829B	1,018B	1,105B	1,015B	1,112B
EBIT	424B	600B	620B	493B	563B
EBITDAR	929B	1,122B	1,221B	1,154B	1,249B
Effective Tax Rate - (Ratio)	-2.71	23.93	15.48	-173.15	38.23
Total Current Taxes	132B	209B	247B	107B	138B
Total Deferred Taxes	-142B	-136B	-189B	-199B	-71.12B
Normalized Net Income	175B	271B	309B	219B	265B
Interest on Long-Term Debt	12.12B	13.93B	16.58B	20.83B	24.51B
Non-Cash Pension Expense	7.96B	17.38B	16.77B	18.7B	18.11B
Supplemental Operating Expense Items
Advertising Expense	-	-	-	-	-
Selling and Marketing Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	456B	526B	633B	730B	730B
Net Rental Expense, Total	12.37B	9.77B	10.57B	16.15B	15.9B
Imputed Operating Lease Interest Expense	2.46B	1.94B	2.05B	2.89B	3.15B
Imputed Operating Lease Depreciation	9.91B	7.83B	8.52B	13.26B	12.76B
Stock-Based Comp., SG&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., Other (Total)	39.43B	43.73B	61.02B	71.51B	73.58B
Total Stock-Based Compensation	39.43B	43.73B	61.02B	71.51B	73.58B

Fiscal Period: March	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	966B	850B	534B	458B	385B
Short Term Investments	-	-	-	-	-
Total Cash And Short Term Investments	966B	850B	534B	458B	385B
Accounts Receivable, Total	707B	618B	575B	612B	651B
Other Receivables	105B	107B	106B	85.17B	73.84B
Total Receivables	813B	724B	682B	698B	725B
Inventory	754B	853B	986B	1,210B	1,217B
Other Current Assets, Total	180B	166B	196B	193B	193B
Total Current Assets	2,713B	2,594B	2,398B	2,559B	2,521B
Gross Property Plant And Equipment	2,189B	2,450B	2,696B	3,210B	3,273B
Accumulated Depreciation	-735B	-867B	-1,005B	-1,221B	-1,305B
Net Property Plant And Equipment	1,454B	1,583B	1,691B	1,990B	1,968B
Long-term Investments	112B	96.58B	99.17B	89.83B	10.8B
Goodwill	4,034B	4,408B	4,791B	5,410B	5,324B
Other Intangibles, Total	3,909B	3,819B	4,270B	4,275B	3,632B
Deferred Tax Assets Long-Term	354B	363B	366B	394B	371B
Other Long-Term Assets, Total	336B	316B	343B	392B	421B
Total Assets	12,912B	13,178B	13,958B	15,109B	14,248B
Liabilities
Accounts Payable, Total	232B	296B	307B	320B	308B
Short-term Borrowings	69M	285M	40.26B	317B	345B
Current Portion of Long-Term Debt	22.08B	204B	299B	50B	204B
Current Portion of Leases	50.19B	53.88B	59.62B	66.21B	64.44B
Current Income Taxes Payable	145B	201B	232B	110B	133B
Other Current Liabilities	1,324B	1,391B	1,543B	1,450B	1,451B
Total Current Liabilities	1,773B	2,146B	2,482B	2,313B	2,507B
Long-Term Debt	4,613B	4,141B	4,043B	4,477B	3,966B
Long-Term Leases	386B	411B	420B	553B	509B
Pension & Other Post Retirement Benefits	159B	146B	128B	144B	135B
Deferred Tax Liability Non Current	543B	452B	271B	114B	35.15B
Other Non Current Liabilities	261B	199B	260B	234B	160B
Total Liabilities	7,735B	7,494B	7,603B	7,835B	7,312B
Common Stock, Total	1,668B	1,676B	1,676B	1,677B	1,695B
Additional Paid In Capital	1,688B	1,709B	1,729B	1,747B	1,776B
Retained Earnings	1,510B	1,480B	1,541B	1,391B	1,188B
Treasury Stock	-59.55B	-116B	-100B	-51.26B	-74.82B
Comprehensive Income and Other	366B	934B	1,508B	2,509B	2,352B
Total Common Equity	5,173B	5,683B	6,354B	7,273B	6,935B
Minority Interest	4.14B	504M	549M	741M	895M
Total Equity	5,177B	5,684B	6,355B	7,274B	6,936B
Total Liabilities And Equity	12,912B	13,178B	13,958B	15,109B	14,248B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	1.56B	1.55B	1.55B	1.57B	1.57B
ECS Total Common Shares Outstanding	1.56B	1.55B	1.55B	1.57B	1.57B
Book Value / Share	3.31K	3.67K	4.09K	4.64K	4.41K
Tangible Book Value	-2,770B	-2,543B	-2,706B	-2,411B	-2,021B
Tangible Book Value Per Share	-1.77K	-1.64K	-1.74K	-1.54K	-1.28K
Total Debt	5,072B	4,811B	4,862B	5,463B	5,089B
Net Debt	4,106B	3,961B	4,328B	5,006B	4,703B
Debt Equivalent of Unfunded Proj. Benefit Obligation	98.7B	80.41B	55.47B	53.05B	37.36B
Debt Equivalent Oper. Leases	98.94B	78.14B	84.56B	129B	127B
Minority Interest, Total (Incl. Fin. Div)	4.14B	504M	549M	741M	895M
Equity Method Investments, Total	112B	96.58B	99.17B	89.83B	10.8B
Account Code - Inventory Valuation	6	6	6	6	6
Inventories - Raw Materials, Total	150B	225B	281B	338B	342B
Inventories - Work In Process, Total	388B	404B	437B	523B	552B
Inventories - Finished Goods, Total	216B	224B	269B	350B	324B
Land - (BS)	95.24B	98.65B	98.23B	106B	104B
Buildings, Total	671B	763B	827B	937B	955B
Machinery, Total	804B	894B	976B	1,125B	1,152B
Full Time Employees	47.1K	47.35K	49.1K	49.28K	47.46K
Accumulated Allowance for Doubtful Accounts (Supple)	8.64B	9.39B	7.36B	8.38B	9.76B

Fiscal Period: March	2021	2022	2023	2024	2025
Net Income	376B	230B	317B	144B	108B
Depreciation & Amortization - CF	126B	136B	153B	173B	172B
Amortization of Goodwill and Intangible Assets - (CF)	405B	419B	485B	522B	549B
Depreciation & Amortization, Total	531B	555B	639B	695B	721B
Amortization of Deferred Charges, Total - (CF)	28.35B	28.56B	25.56B	32.59B	40.41B
(Gain) Loss From Sale Of Asset	-232B	-7.17B	-6.8B	-1.78B	-5.7B
(Gain) Loss on Sale of Investments - (CF)	59.28B	-11.2B	3.99B	20.76B	-602M
Asset Writedown & Restructuring Costs	25.45B	54.52B	64.39B	150B	107B
(Income) Loss On Equity Investments - (CF)	-76M	15.37B	8.63B	-6.47B	3.99B
Stock-Based Compensation (CF)	37.66B	43.37B	60.67B	70.87B	72.87B
Other Operating Activities, Total	-129B	74.99B	-110B	-133B	70.15B
Change In Accounts Receivable	-9.32B	127B	75.13B	15.1B	-58.96B
Change In Inventories	25.98B	-46.15B	-79.16B	-116B	-34.97B
Change In Accounts Payable	36.62B	125B	-84.8B	-9.9B	-7.12B
Change in Other Net Operating Assets	260B	-66.29B	63.57B	-145B	41.68B
Cash from Operations	1,011B	1,123B	977B	716B	1,057B
Capital Expenditure	-111B	-123B	-141B	-175B	-201B
Sale of Property, Plant, and Equipment	46.45B	1.82B	962M	8.61B	78M
Cash Acquisitions	-	-49.67B	-	-	-
Divestitures	530B	28.2B	7.96B	19.96B	20.56B
Sale (Purchase) of Intangible assets	-125B	-62.78B	-493B	-305B	-147B
Investment in Marketable and Equity Securities, Total	62.01B	8.58B	12.1B	1.26B	-11.41B
Other Investing Activities, Total	-8.85B	-1.01B	5.56B	-12.95B	-28.45B
Cash from Investing	394B	-198B	-607B	-464B	-367B
Short Term Debt Issued, Total	-	-	40B	277B	27.49B
Long-Term Debt Issued, Total	1,180B	249B	75B	100B	1,024B
Total Debt Issued	1,180B	249B	115B	377B	1,052B
Short Term Debt Repaid, Total	-149B	-2M	-	-	-
Long-Term Debt Repaid, Total	-1,691B	-850B	-400B	-375B	-1,366B
Total Debt Repaid	-1,840B	-850B	-400B	-375B	-1,366B
Repurchase of Common Stock	-2.14B	-77.53B	-26.93B	-2.33B	-51.86B
Common Dividends Paid	-283B	-284B	-279B	-287B	-302B
Common & Preferred Stock Dividends Paid	-283B	-284B	-279B	-287B	-302B
Other Financing Activities, Total	-142B	-109B	-118B	-66.42B	-82.75B
Cash from Financing	-1,088B	-1,070B	-709B	-354B	-751B
Foreign Exchange Rate Adjustments	12.5B	28.76B	22.93B	26.2B	-11.38B
Miscellaneous Cash Flow Adjustments	-	-	-	-	-
Net Change in Cash	329B	-117B	-316B	-75.73B	-72.69B
Supplemental Items
Cash Interest Paid	107B	108B	109B	100B	113B
Cash Income Tax Paid (Refund)	202B	140B	186B	202B	150B
Levered Free Cash Flow	784B	929B	480B	116B	736B
Unlevered Free Cash Flow	865B	1,005B	553B	188B	817B
Change In Net Working Capital	-238B	-190B	-74.38B	439B	21.8B
Net Debt Issued / Repaid	-661B	-600B	-285B	1.51B	-314B

Fiscal Period: March	2021	2022	2023	2024	2025
Profitability
Return on Assets	2.06	2.87	2.85	2.12	2.4
Return on Total Capital	2.59	3.61	3.57	2.57	2.84
Return On Equity %	7.6	4.24	5.27	2.12	1.52
Return on Common Equity	7.6	4.24	5.27	2.11	1.52
Margin Analysis
Gross Profit Margin %	68.91	68.41	68.88	66.43	65.7
SG&A Margin	27.38	24.83	24.76	24.72	24.11
EBITDA Margin %	28.67	31.17	30.06	26.68	26.92
EBITA Margin %	25.92	28.53	27.44	23.81	24.26
EBIT Margin %	13.25	16.8	15.39	11.57	12.29
Income From Continuing Operations Margin %	11.76	6.45	7.87	3.38	2.36
Net Income Margin %	11.76	6.45	7.87	3.38	2.36
Net Avail. For Common Margin %	11.76	6.45	7.87	3.38	2.36
Normalized Net Income Margin	5.49	7.6	7.67	5.14	5.78
Levered Free Cash Flow Margin	24.51	26.02	11.93	2.71	16.06
Unlevered Free Cash Flow Margin	27.06	28.17	13.74	4.4	17.84
Asset Turnover
Asset Turnover	0.25	0.27	0.3	0.29	0.31
Fixed Assets Turnover	2.25	2.35	2.46	2.32	2.32
Receivables Turnover (Average Receivables)	4.64	5.39	6.75	7.18	7.25
Inventory Turnover (Average Inventory)	1.31	1.4	1.36	1.3	1.29
Short Term Liquidity
Current Ratio	1.53	1.21	0.97	1.11	1.01
Quick Ratio	1	0.73	0.49	0.5	0.44
Operating Cash Flow to Current Liabilities	0.57	0.52	0.39	0.31	0.42
Days Sales Outstanding (Average Receivables)	78.65	67.75	54.06	50.98	50.34
Days Outstanding Inventory (Average Inventory)	277.83	260.17	267.91	280.77	281.89
Average Days Payable Outstanding	81.93	78.56	79.42	69.38	72.64
Cash Conversion Cycle (Average Days)	274.56	249.35	242.54	262.38	259.6
Long Term Solvency
Total Debt/Equity	97.96	84.64	76.51	75.11	73.37
Total Debt / Total Capital	49.49	45.84	43.34	42.89	42.32
LT Debt/Equity	96.57	80.1	70.22	69.15	64.52
Long-Term Debt / Total Capital	48.78	43.38	39.79	39.49	37.22
Total Liabilities / Total Assets	59.9	56.87	54.47	51.86	51.32
EBIT / Interest Expense	3.24	4.9	5.3	4.27	4.31
EBITDA / Interest Expense	7.3	9.43	10.76	10.3	9.84
(EBITDA - Capex) / Interest Expense	6.45	8.42	9.56	8.78	8.3
Total Debt / EBITDA	5.31	4.17	3.86	4.6	3.96
Net Debt / EBITDA	4.3	3.43	3.44	4.21	3.66
Total Debt / (EBITDA - Capex)	6.01	4.67	4.35	5.39	4.7
Net Debt / (EBITDA - Capex)	4.87	3.84	3.87	4.94	4.34
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-2.84	11.61	12.85	5.87	7.45
Gross Profit, 1 Yr. Growth %	0.1	11.79	13.62	2.09	6.28
EBITDA, 1 Yr. Growth %	13.08	21.34	8.78	-6.03	7.81
EBITA, 1 Yr. Growth %	16.95	22.86	8.47	-8.13	8.82
EBIT, 1 Yr. Growth %	42.8	41.54	3.27	-20.4	12.71
Earnings From Cont. Operations, 1 Yr. Growth %	749.34	-38.81	37.74	-54.52	-25
Net Income, 1 Yr. Growth %	749.9	-38.82	37.8	-54.56	-25.08
Normalized Net Income, 1 Yr. Growth %	105.46	54.72	12.83	-29.04	18.83
Diluted EPS Before Extra, 1 Yr. Growth %	745.88	-38.96	38.44	-54.86	-26.25
Accounts Receivable, 1 Yr. Growth %	5.48	-12.72	-6.82	6.43	6.36
Inventory, 1 Yr. Growth %	-0.75	13.17	15.62	22.65	0.62
Net Property, Plant and Equip., 1 Yr. Growth %	4.87	8.86	6.85	17.65	-1.08
Total Assets, 1 Yr. Growth %	0.71	2.06	5.92	8.25	-5.7
Tangible Book Value, 1 Yr. Growth %	-19.95	-8.18	6.41	-10.89	-16.2
Common Equity, 1 Yr. Growth %	9.52	9.86	11.81	14.47	-4.65
Cash From Operations, 1 Yr. Growth %	50.94	11.1	-13	-26.69	47.58
Capital Expenditures, 1 Yr. Growth %	-12.49	10.83	14.12	24.71	14.47
Levered Free Cash Flow, 1 Yr. Growth %	-15.68	18.53	-48.31	-75.95	516.06
Unlevered Free Cash Flow, 1 Yr. Growth %	-15.37	16.17	-44.97	-66.1	326.66
Dividend Per Share, 1 Yr. Growth %	0	0	0	4.44	4.26
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	23.48	4.14	12.23	9.3	6.66
Gross Profit, 2 Yr. CAGR %	23.47	6.05	12.7	7.7	4.16
EBITDA, 2 Yr. CAGR %	40.53	12.41	10.94	-1.94	-2
EBITA, 2 Yr. CAGR %	95.66	85.27	61.44	30.08	33.94
EBIT, 2 Yr. CAGR %	39.88	42.15	20.88	-9.34	-4.69
Earnings From Cont. Operations, 2 Yr. CAGR %	66.88	127.96	-8.2	-20.85	-41.6
Net Income, 2 Yr. CAGR %	66.77	128.04	-8.18	-20.87	-41.65
Normalized Net Income, 2 Yr. CAGR %	48.96	78.27	32.66	-10.41	-7.36
Diluted EPS Before Extra, 2 Yr. CAGR %	30.73	127.23	-8.07	-20.95	-42.3
Accounts Receivable, 2 Yr. CAGR %	3.72	-4.05	-9.81	-0.41	6.4
Inventory, 2 Yr. CAGR %	-9.46	5.98	14.39	19.08	11.09
Net Property, Plant and Equip., 2 Yr. CAGR %	4.48	6.85	7.85	12.12	7.88
Total Assets, 2 Yr. CAGR %	-3.24	1.38	3.97	7.08	1.04
Tangible Book Value, 2 Yr. CAGR %	-14.73	-14.27	-1.16	-2.63	-13.59
Common Equity, 2 Yr. CAGR %	-0.09	9.69	10.83	13.13	4.47
Cash From Operations, 2 Yr. CAGR %	75.43	29.5	-1.68	-20.14	4.01
Capital Expenditures, 2 Yr. CAGR %	19.65	-1.52	12.46	19.3	19.48
Levered Free Cash Flow, 2 Yr. CAGR %	23.02	-0.04	-21.72	-64.74	23.76
Unlevered Free Cash Flow, 2 Yr. CAGR %	33.21	-0.85	-20.04	-56.81	21.52
Dividend Per Share, 2 Yr. CAGR %	0	0	0	2.2	4.35
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	21.78	19.39	6.96	10.06	8.68
Gross Profit, 3 Yr. CAGR %	20.01	19.09	8.52	9.05	7.23
EBITDA, 3 Yr. CAGR %	36.57	33.82	11.2	4.97	1.39
EBITA, 3 Yr. CAGR %	67.05	67.54	55.02	33.78	22.82
EBIT, 3 Yr. CAGR %	33.56	40.42	27.83	5.17	-2.11
Earnings From Cont. Operations, 3 Yr. CAGR %	26.3	19.44	92.72	-27.36	-22.26
Net Income, 3 Yr. CAGR %	26.24	19.39	92.79	-27.37	-22.3
Normalized Net Income, 3 Yr. CAGR %	28.58	50.84	53.5	7.69	-0.99
Diluted EPS Before Extra, 3 Yr. CAGR %	0.2	1.42	92.63	-27.47	-22.76
Accounts Receivable, 3 Yr. CAGR %	25.16	-2.08	-4.98	-4.7	1.8
Inventory, 3 Yr. CAGR %	52.41	-2.47	9.1	17.08	12.58
Net Property, Plant and Equip., 3 Yr. CAGR %	39.39	5.92	6.85	11.03	7.53
Total Assets, 3 Yr. CAGR %	46.5	-1.51	2.87	5.38	2.64
Tangible Book Value, 3 Yr. CAGR %	291.71	-12.6	-7.87	-4.51	-7.38
Common Equity, 3 Yr. CAGR %	37.33	3.12	10.39	12.03	6.86
Cash From Operations, 3 Yr. CAGR %	38.82	50.65	13.42	-10.85	-2
Capital Expenditures, 3 Yr. CAGR %	18.4	16.64	3.44	16.41	17.67
Levered Free Cash Flow, 3 Yr. CAGR %	41.31	21.5	-19.75	-47.18	-7.49
Unlevered Free Cash Flow, 3 Yr. CAGR %	44.98	27.26	-18.51	-39.93	-6.68
Dividend Per Share, 3 Yr. CAGR %	0	0	0	1.46	2.88
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	12.09	15.56	17.87	15.25	6.84
Gross Profit, 5 Yr. CAGR %	11.61	15.76	16.82	14.4	6.75
EBITDA, 5 Yr. CAGR %	21.68	30.24	27.45	19.64	6.97
EBITA, 5 Yr. CAGR %	38.7	52.01	44.11	36.21	30.24
EBIT, 5 Yr. CAGR %	21.28	36.73	28.36	17.9	13.67
Earnings From Cont. Operations, 5 Yr. CAGR %	35.13	14.78	11.17	1.31	19.55
Net Income, 5 Yr. CAGR %	36.22	14.89	11.15	1.28	19.53
Normalized Net Income, 5 Yr. CAGR %	14.8	30.27	30.21	22.62	25.43
Diluted EPS Before Extra, 5 Yr. CAGR %	18.63	-0.05	-3.2	-8.2	18.93
Accounts Receivable, 5 Yr. CAGR %	13.45	11.62	9.78	-1.42	-0.58
Inventory, 5 Yr. CAGR %	24.31	30.43	35.88	5.64	9.89
Net Property, Plant and Equip., 5 Yr. CAGR %	21.38	24.59	25.8	8.36	7.26
Total Assets, 5 Yr. CAGR %	27.55	24.83	27.72	1.84	2.13
Tangible Book Value, 5 Yr. CAGR %	45.4	68.3	125.82	-8.74	-10.2
Common Equity, 5 Yr. CAGR %	21.56	24.57	26.04	7.02	7.98
Cash From Operations, 5 Yr. CAGR %	108.77	33.86	20.93	16.88	9.56
Capital Expenditures, 5 Yr. CAGR %	17.93	14.86	15.99	17.69	9.58
Levered Free Cash Flow, 5 Yr. CAGR %	55.7	27.67	11.58	-25.92	-4.57
Unlevered Free Cash Flow, 5 Yr. CAGR %	60.07	29.27	14.28	-17.39	-4.38
Dividend Per Share, 5 Yr. CAGR %	0	0	0	0.87	1.72